AqVida and Phyton Biotech Receive European Quality Medicines Directorate Approval for Injectable Finished Dosage Formulation of AqVida Anti-Cancer Paclitaxel

0


[ad_1]

FORT WORTH, Texas – (COMMERCIAL THREAD) – Phyton Biotech, a German / North American plant cell fermentation (PCF®) technology company, and AqVida, a German manufacturer of finished dosage formulations (FDF) in oncology, are pleased to announce today that ‘they have received European approval from the EDQM (European Directorate for the Quality of Medicines) for the injectable FDF paclitaxel from AqVida.

Phyton Biotech is the world’s leading manufacturer of active pharmaceutical ingredients (APIs) paclitaxel, using its proprietary PCF® technological process. As part of the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of the API paclitaxel for the generic formulation Taxol of AqVida, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. . AqVida’s state-of-the-art robotic manufacturing line, designed for filling cytotoxic injectables, will be used to produce AqVida’s generic oncology drugs to treat common types of cancer.

“We chose to work with Phyton because of the company’s superior fermentation-produced API, compared to naturally or semi-synthetically produced alternatives,†said Wolfgang Heinze, CEO of AqVida. “The approval of our FDF injectable paclitaxel by the European Directorate for the Quality of Medicines is a major step for our company. ”

Recognized for its innovative and broad portfolio of generic oncology drugs, AqVida is one of the leading German suppliers of oncology drugs which distributes its products worldwide.

“We are proud to partner with AqVida and help expand its oncology product line,†said Colin Marr, President of Phyton Biotech. “Phyton is committed to working with trusted pharmaceutical partners who seek to improve the quality of oncology drugs. ”

About Phyton Biotech

Phyton Biotech, a 100% subsidiary of DFB Pharmaceuticals, is the world leader in plant cell fermentation (PCF®) technology, offering comprehensive services for the development and commercialization of molecules, extracts and recombinant products based on plants, serving the pharmaceutical industry, Chinese Traditional medicine, cosmetics, agricultural and food ingredients industries. By using PCF®, Phyton Biotech offers a balanced path in terms of time, risk and cost towards commercially viable production processes, overcoming limitations often encountered with traditional plant extraction and chemical synthesis.

As a leader in biotechnology with GMP certified facilities in Germany and Canada, Phyton Biotech has a successful track record in developing and implementing innovative contract development solutions for clients around the world. The company is now the world’s largest producer of paclitaxel and docetaxel via PCF®, with the ability to meet more than a third of the global demand for these essential active pharmaceutical ingredients. For more information, please visit phytonbiotech.com.

About AqVida

AqVida is a German pharmaceutical manufacturer of injectable finished dosage form (FDF) drugs. Its mission is entirely dedicated and specialized in the development, registration, manufacture and distribution of injectable FDF mainly for the oncology sector. She has developed a portfolio of generic injectable oncology drugs for the treatment of the most common types of cancer. AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.

[ad_2]

Share.

Comments are closed.